Hygienic rationing of mesalazine as salicylic acid derivative

Мұқаба

Дәйексөз келтіру

Толық мәтін

Аннотация

Introduction. Hygienic rationing of the content of adverse substances in the air on the basis of an experimental study of their toxicity is aimed at the elaboration and creation of safe working conditions.

Material and methods. The toxic properties of the salicylic acid derivative (Mesalazine) have been studied in the experiments on out-bred and linear mice, rats, Guinea pigs, and rabbits kept in standard vivarium conditions and quarantined. In the experiments, various modes (single, repeated, chronic) and ways of exposure (intragastric, inhalation, epicutaneous) were simulated. The average lethal dose (LD50) of Mesalazine and the threshold of a single acute exposure (Limas) were determined; irritant effect on the skin and mucous membranes, cumulative and allergenic activity were estimated. In subacute and chronic intake, the main target organs were determined based on the results of biochemical and hematological studies.

Results. By the value of the average lethal doses Mesalazine has been established to have to be classified as a substance of the 3rd hazard class (moderately hazardous). There were no significant differences in the species and the gender susceptibility of the animals to Mesalazine: the coefficient of species differences was 2.84; the coefficient of the gender susceptibility was 1.2, which was less than 3 units. In terms of the degree of specific blood damage, Mesalazine belongs to class V (no effect of the selective influence of the drug on the imbalance of various hemoglobin forms). Mesalazine has a weak ability to cumulate, have no irritating effects on the eyes and skin. Skin-resorptive and sensitizing effects were not revealed. Limas under the conditions of dynamic inhalation exposure is set at 30.4 mg/m3.

Conclusion. Maximum allowable concentration (MAC) of Mesalazine in the air of the working area as 0.5 mg/m3 is recommended (hazard class II). Compliance with this standard will ensure the health preservation and will eliminate the risk of developing occupational diseases.

Авторлар туралы

Larisa Gorokhova

Research Institute for Complex Problems of Hygiene and Occupational Diseases; Novokuznetsk Institute (Branch) of FSBEI HE “Kemerovo State University”

Хат алмасуға жауапты Автор.
Email: ponomarikova@mail.ru
ORCID iD: 0000-0002-0545-631X

MD, Ph.D., leading researcher of the Laboratory for experimental hygienic research of the Research Institute for Complex Problems of Hygiene and Occupational Diseases, Novokuznetsk, 654041, Russian Federation.

e-mail: ponomarikova@mail.ru

Ресей

N. Martynova

Research Institute for Complex Problems of Hygiene and Occupational Diseases

Email: noemail@neicon.ru
Ресей

N. Mikhailova

Research Institute for Complex Problems of Hygiene and Occupational Diseases; Novokuznetsk Institute (Branch) of FSBEI HE “Kemerovo State University”

Email: noemail@neicon.ru
Ресей

Әдебиет тізімі

  1. Izmerov N.F., Kasparov A.A. Occupational medicine. [Meditsina truda]. Moscow: Meditsina; 2002. (in Russian)
  2. Gorokhova L.G., Ulanova E.V., Shavcova G.M., Erdeeva S.V., Blazhina O.N. Health state of workers in chemical and pharmaceutic industry. Meditsina truda i promyshlennaya ekologiya. 2018; (6): 38-42. (in Russian)
  3. Rakhmanin Yu.A. Updating the problems of human ecology and environmental health and the ways of solving them. Gigiena i sanitariya. 2012; (5): 4-8. (in Russian)
  4. Golukhova E.Z., Ryabinina M.N. Current aspects of antiplatelet therapy. Kreativnaya kardiologiya. 2013; (1): 45-58. (in Russian)
  5. Zlatkina A.R. Modern therapeutic tactics of inflammatory bowel diseases. Gastroenterologiya. Prilozhenie k zhurnalu Consilium Medicum. 2004; (1): 28-31. (in Russian)
  6. Stepanov Yu.M., Stoykevich M.V., Sorochan O.V. Application of 5-aminisalicylic acid preparations in the treatment of inflammatory bowel diseases. Gastroehnterologiya. 2016; 61 (3): 80-87. (in Russian)
  7. Sitkin S.I., Zhigalova T.N., Konovalova N.O., Tkachenko Ye.I. The combined mesalazine treatment and medical tactics at inflammatory bowel diseases. Klinicheskie perspektivy v gastroenterologii, gepatologii. 2010; (5): 34-40. (in Russian)
  8. Bokemeyer B., Hommes D., Gill I., Broberg P., Dignass A. Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. J. Crohns. Colitis. 2012; 6(4): 476-82.
  9. Shapina M.V., Khalif I.L. Use of 5-aminosalicylic acid for treatment of ulcerative colitis in different dosage modes. Meditsinskiy sovet. 2017; (15): 44-50. (in Russian)
  10. Williams C., Panaccione R., Ghosh S., Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 2011; 4(4): 237-248.
  11. Hauso O., Martinsen T.C., Waldum H 5-Aminosalicylic acid, a specific drug for ulcerative colits. Scandinavian Journal of Gastroenterology. 2015; 50 (8): 933-941.
  12. Semina I.I., Kabanova T.V., Porfireva N.N., Safina Z.Z., Sitenkov A.Yu., Elizarova A.S., Mustafin R.I. A study of anti-inflammatory activity of polymer-drug complex microparticles with mesalazine on model of experimental colits in rats. Sovremennye problemy nauki i obrazovaniya. 2016; (6): 244. (in Russian)
  13. Nielsen O.H., Bukhave K., Elmgreen J. Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Digestive Diseases and Sciences. 1987; 32: 577-82.
  14. Klotz U. The pharmacological profile and clinical use of mesalazine (5-aminosalicylic acid). Arzneimittel-Forschung. 2012; 62(2): 53-58
  15. Gordon G.L., Zakko S., Murthy U., Sedghi S., Pruitt R., Barrett A.C. et al. Once-daily Mesalamine formulation for maintenance of remission in ulcerative colitis: A randomized, placebo-controlled clinical trial. J. Clin. Gastroenterol. 2016; 50(4): 318-25. https://doi.org/10.1097/MCG.0000000000000414
  16. Sitenkov A.Yu., Safina Z.Z., Elizarova A.S., Porfireva N.N., Kabanova T.V., Semina I.I., Mustafin R.I. A study of anti-inflammatory activity of polymer-drug complex microparticles with mesalazine on model of experimental colits in rats. Sovremennye problemy nauki i obrazovaniya. 2016; (6): 244-6. (in Russian)
  17. Ordás I., Eckmann L., Talamini M. et al. Ulcerative colitis. Lancet. 2012; 380:1606.
  18. Mashkovsky M.D. Medicinal products [Lekarstvennye sredstva]. Moscow: Novaya volna; 2012. (in Russian)
  19. Gathuru I., Dolan D., Buchanich J., Marsh G.M. Health Hazards in the Pharmaceutical Industry: A Review of the Literature. Pharmaceutical Regulatory Affairs. 2015; 4(3); 1-15, https://doi.org/10.4172/2167-7689.1000145
  20. Gorokhova L.G., Martynova N.A., Kizichenko N.V., Logunova T.D. Hygienic aspects of health status of the workers in chemical and pharmaceutical production. Medicina v Kuzbasse. 2017; (3): 11-16. (in Russian)
  21. Lim R.K., Rink K.G., Glass H.G., Soaje-Echague E.A. Method for the evaluation of cumulation and tolerance by the determination of acute and subchronic median effective doses. Arch. Intern. Pharm. 1961; 130: 336-52.
  22. Gorokhova L.G., Sosedova L.M., Martynova N.A. Preclinical study as a basis for hygienic regulation of benzofuran derivatives. Meditsina truda i promyshlennaya ekologiya. 2011; (7): 30-3. (in Russian)
  23. Gorokhova L.G., Martynova N.A., Kolova E.P. On hygienic regulation of benzodiazepines. Meditsina truda i promyshlennaya ekologiya. 2016; (5): 32-35. (in Russian)
  24. Medik V.A., Tokmachev M.S., Fishman B.B. Statistics in medicine and biology. [Statistika v meditsine i biologii]. Moscow: Meditsina; 2000. (in Russian)
  25. Rebrova O.Yu. Statistical analysis of medical data. Application of the STATISTICA software package [Statisticheskiy analiz meditsinskikh dannykh. Primenenie paketa prikladnykh programm STATISTICA]. Moscow: Media Sfera; 2002. (in Russian)
  26. Martynova N.A., Gorokhova L.G. Evaluation of toxicity of 3-bromo aminobenzene sulfate as a basis for prediction of occupational risk to health. Toksikologicheskij vestnik. 2014; (5): 21-25. (in Russian)
  27. Artyukhov V.G., Kalaeva E.A., Putintseva O.V., Polyubez’eva A.I. The modification of structural and functional properties of human hemoglobin induced by nitroglycerin under different oxygen regime conditions. Biomeditsinskaya Khimiya. 2016; (3): 251-8. (in Russian)
  28. Vasilenko N.M. Effects of aromatic nitro compounds on human and animals. Gigiena i sanitariya. 1972; (45): 31-5. (in Russian)
  29. Zabrodsky P.F. Immunotoxicology of organophosphorus compounds. [Immunotoksikologiya fosfororganicheskikh soedineniy]. Saratov: Saratovskiy istochnik; 2016. (in Russian)
  30. Martynova N.A., Gorokhova L.G. Experimental substantiation of a tentative safe level of the exposure to 5-phenylazosalicylic acid in the air of the working area. In: Professional and environmental risks in occupational medicine and human ecology. Ways to solve the problem from theory to practice: Materials of the XLVIII scientific-practical conference “Hygiene, healthcare organization and occupational pathology” and the seminar “Actual issues of modern occupational pathology”. [Materialy XLVIII nauchno-prakticheskoy konferentsii “Gigiena, organizatsiya zdravookhraneniya i profpatologiya” i seminara “Aktual’nye voprosy sovremennoy profpatologii”]. Kemerovo: Primula; 2013: 50-2. (in Russian)

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Gorokhova L.G., Martynova N.A., Mikhailova N.N., 2024


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 37884 от 02.10.2009.